Cable Hill Partners’s Sage Therapeutics SAGE Stock Holding History

Cable Hill Partners’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-19	Closed	-$3K	–	579
2019 Q1	$3K	Sell	19 -15	-44%	-$2.17K	﹤0.01%	713
2018 Q4	$3K	Hold	34	–	–	﹤0.01%	672
2018 Q3	$5K	Sell	34 -6	-15%	-$926	﹤0.01%	580
2018 Q2	$6K	Hold	40	–	–	﹤0.01%	618
2018 Q1	$6K	Sell	40 -66	-62%	-$11.2K	﹤0.01%	620
2017 Q4	$18K	Hold	106	–	–	0.01%	438
2017 Q3	$7K	Sell	106 -2	-2%	-$157	﹤0.01%	685
2017 Q2	$9K	Hold	108	–	–	﹤0.01%	433
2017 Q1	$8K	Sell	108 -4	-4%	-$234	﹤0.01%	450
2016 Q4	$6K	Hold	112	–	–	﹤0.01%	521
2016 Q3	$5K	Sell	112 -62	-36%	-$2.52K	﹤0.01%	572
2016 Q2	$6K	Hold	174	–	–	﹤0.01%	477
2016 Q1	$6K	Buy	174 +53	+44%	+$1.87K	﹤0.01%	451
2015 Q4	$8K	Buy	121 +33	+38%	+$1.64K	0.01%	397
2015 Q3	$4K	Hold	88	–	–	﹤0.01%	546
2015 Q2	$7K	Buy	+88	New	+$5.66K	0.01%	529

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Cable Hill Partners's SAGE Position: Q2 2019 in Review

Cable Hill Partners sold out of Sage Therapeutics (SAGE) in Q2 2019, closing a stake of 19 shares — an estimated $3K sold.

Cable Hill Partners first reported a position in SAGE in Q2 2015 and held it in 16 quarters. The position peaked at $18K in Q4 2017. 272 funds tracked by Wall St. Rank hold SAGE as of Q2 2019.

Cable Hill Partners reported no remaining Sage Therapeutics position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 19 Sage Therapeutics shares in Q2 2019, an estimated $3K.
Cable Hill Partners first reported a position in Sage Therapeutics in Q2 2015 and held it in 16 quarters.
Cable Hill Partners's Sage Therapeutics position peaked at $18K in Q4 2017.
272 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.